{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:02:02Z","timestamp":1790704922272,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,2,5]],"date-time":"2016-02-05T00:00:00Z","timestamp":1454630400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,2,5]],"date-time":"2016-02-05T00:00:00Z","timestamp":1454630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Rift Valley Fever virus (RVFV) causes recurrent outbreaks of acute life-threatening human and livestock illness in Africa and the Arabian Peninsula. No licensed vaccines are currently available for humans and those widely used in livestock have major safety concerns. A \u2018One Health\u2019 vaccine development approach, in which the same vaccine is co-developed for multiple susceptible species, is an attractive strategy for RVFV. Here, we utilized a replication-deficient chimpanzee adenovirus vaccine platform with an established human and livestock safety profile, ChAdOx1, to develop a vaccine for use against RVFV in both livestock and humans. We show that single-dose immunization with ChAdOx1-GnGc vaccine, encoding RVFV envelope glycoproteins, elicits high-titre RVFV-neutralizing antibody and provides solid protection against RVFV challenge in the most susceptible natural target species of the virus-sheep, goats and cattle. In addition we demonstrate induction of RVFV-neutralizing antibody by ChAdOx1-GnGc vaccination in dromedary camels, further illustrating the potency of replication-deficient chimpanzee adenovirus vaccine platforms. Thus, ChAdOx1-GnGc warrants evaluation in human clinical trials and could potentially address the unmet human and livestock vaccine needs.<\/jats:p>","DOI":"10.1038\/srep20617","type":"journal-article","created":{"date-parts":[[2016,2,5]],"date-time":"2016-02-05T10:50:48Z","timestamp":1454669448000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":106,"title":["Chimpanzee Adenovirus Vaccine Provides Multispecies Protection against Rift Valley Fever"],"prefix":"10.1038","volume":"6","author":[{"given":"George M.","family":"Warimwe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Gesharisha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. Veronica","family":"Carr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simeon","family":"Otieno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kennedy","family":"Otingah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Charleston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Okoth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lopez-Gil","family":"Elena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gema","family":"Lorenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"El-Behiry","family":"Ayman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naif K.","family":"Alharbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Musaad A.","family":"Al-dubaib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Brun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah C.","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishvanath","family":"Nene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian V. S.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,2,5]]},"reference":[{"key":"BFsrep20617_CR1","doi-asserted-by":"publisher","first-page":"28","DOI":"10.4269\/ajtmh.2010.09-0319","volume":"83","author":"R Sang","year":"2010","unstructured":"Sang, R. et al. Rift Valley fever virus epidemic in Kenya, 2006\/2007: the entomologic investigations. Am J Trop Med Hyg 83, 28\u201337, doi: 10.4269\/ajtmh.2010.09-0319 (2010).","journal-title":"Am J Trop Med Hyg"},{"key":"BFsrep20617_CR2","doi-asserted-by":"publisher","first-page":"963","DOI":"10.3201\/eid1606.091266","volume":"16","author":"SF Andriamandimby","year":"2010","unstructured":"Andriamandimby, S. F. et al. Rift Valley fever during rainy seasons, Madagascar, 2008 and 2009. Emerg Infect Dis 16, 963\u2013970, doi: 10.3201\/eid1606.091266 (2010).","journal-title":"Emerg Infect Dis"},{"key":"BFsrep20617_CR3","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1086\/378747","volume":"37","author":"TA Madani","year":"2003","unstructured":"Madani, T. A. et al. Rift Valley fever epidemic in Saudi Arabia: epidemiological, clinical, and laboratory characteristics. Clin Infect Dis 37, 1084\u20131092, doi: 10.1086\/378747 (2003).","journal-title":"Clin Infect Dis"},{"key":"BFsrep20617_CR4","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1002\/path.1700340418","volume":"34","author":"R Daubney","year":"1931","unstructured":"Daubney, R., Hudson, J. R. & Granham, P. C. Enzootic Hepatitis or Rift Valley fever: an undescribed virus disease of sheep, cattle and man from East Africa Journal of Pathology and Bacteriology 34, 545\u2013579 (1931).","journal-title":"Journal of Pathology and Bacteriology"},{"key":"BFsrep20617_CR5","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1073\/pnas.0806490106","volume":"106","author":"A Anyamba","year":"2009","unstructured":"Anyamba, A. et al. Prediction of a Rift Valley fever outbreak. Proc Natl Acad Sci USA 106, 955\u2013959, doi: 10.1073\/pnas.0806490106 (2009).","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFsrep20617_CR6","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.coviro.2012.02.017","volume":"2","author":"BH Bird","year":"2012","unstructured":"Bird, B. H. & Nichol, S. T. Breaking the chain: Rift Valley fever virus control via livestock vaccination. Curr Opin Virol 2, 315\u2013323, doi: 10.1016\/j.coviro.2012.02.017 (2012).","journal-title":"Curr Opin Virol"},{"key":"BFsrep20617_CR7","first-page":"65","volume":"10","author":"BC Easterday","year":"1965","unstructured":"Easterday, B. C. Rift valley fever. Adv Vet Sci 10, 65\u2013127 (1965).","journal-title":"Adv Vet Sci"},{"key":"BFsrep20617_CR8","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/path.1700860131","volume":"86","author":"GR Scott","year":"1963","unstructured":"Scott, G. R., Coackley, W., Roach, R. W. & Cowdy, N. R. Rift Valley fever in camels. J Pathol Bacteriol 86, 229\u2013231 (1963).","journal-title":"J Pathol Bacteriol"},{"key":"BFsrep20617_CR9","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.3201\/eid1710.110397","volume":"17","author":"AB El Mamy","year":"2011","unstructured":"El Mamy, A. B. et al. Unexpected Rift Valley fever outbreak, northern Mauritania. Emerg Infect Dis 17, 1894\u20131896, doi: 10.3201\/eid1710.110397 (2011).","journal-title":"Emerg Infect Dis"},{"key":"BFsrep20617_CR10","doi-asserted-by":"publisher","first-page":"22","DOI":"10.4269\/ajtmh.2010.09-0318","volume":"83","author":"M Mohamed","year":"2010","unstructured":"Mohamed, M. et al. Epidemiologic and clinical aspects of a Rift Valley fever outbreak in humans in Tanzania, 2007. Am J Trop Med Hyg 83, 22\u201327, doi: 10.4269\/ajtmh.2010.09-0318 (2010).","journal-title":"Am J Trop Med Hyg"},{"key":"BFsrep20617_CR11","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1086\/345671","volume":"36","author":"M Al-Hazmi","year":"2003","unstructured":"Al-Hazmi, M. et al. Epidemic Rift Valley fever in Saudi Arabia: a clinical study of severe illness in humans. Clin Infect Dis 36, 245\u2013252, doi: 10.1086\/345671 (2003).","journal-title":"Clin Infect Dis"},{"key":"BFsrep20617_CR12","doi-asserted-by":"crossref","first-page":"213","DOI":"10.4049\/jimmunol.62.2.213","volume":"62","author":"KC Smithburn","year":"1949","unstructured":"Smithburn, K. C. & Mahaffy, A. F. et al. Rift Valley fever; accidental infections among laboratory workers. J Immunol 62, 213\u2013227 (1949).","journal-title":"J Immunol"},{"key":"BFsrep20617_CR13","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1128\/JVI.02095-06","volume":"81","author":"BH Bird","year":"2007","unstructured":"Bird, B. H., Khristova, M. L., Rollin, P. E., Ksiazek, T. G. & Nichol, S. T. Complete genome analysis of 33 ecologically and biologically diverse Rift Valley fever virus strains reveals widespread virus movement and low genetic diversity due to recent common ancestry. J Virol 81, 2805\u20132816, doi: 10.1128\/JVI.02095-06 (2007).","journal-title":"J Virol"},{"key":"BFsrep20617_CR14","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1159\/000157178","volume":"135","author":"B Dungu","year":"2013","unstructured":"Dungu, B., Donadeu, M. & Bouloy, M. Vaccination for the control of Rift Valley fever in enzootic and epizootic situations. Dev Biol (Basel) 135, 61\u201372, doi: 10.1159\/000157178 (2013).","journal-title":"Dev Biol (Basel)"},{"key":"BFsrep20617_CR15","doi-asserted-by":"publisher","first-page":"3222","DOI":"10.1016\/j.vaccine.2011.02.037","volume":"29","author":"JM Rusnak","year":"2011","unstructured":"Rusnak, J. M., Gibbs, P., Boudreau, E., Clizbe, D. P. & Pittman, P. Immunogenicity and safety of an inactivated Rift Valley fever vaccine in a 19-year study. Vaccine 29, 3222\u20133229, doi: 10.1016\/j.vaccine.2011.02.037 (2011).","journal-title":"Vaccine"},{"key":"BFsrep20617_CR16","doi-asserted-by":"crossref","unstructured":"Colloca, S. et al. Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci Transl Med 4, 115ra112, doi: 10.1126\/scitranslmed.3002925 (2012).","DOI":"10.1126\/scitranslmed.3002925"},{"key":"BFsrep20617_CR17","doi-asserted-by":"publisher","first-page":"e40385","DOI":"10.1371\/journal.pone.0040385","volume":"7","author":"MD Dicks","year":"2012","unstructured":"Dicks, M. D. et al. A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity. PLoS One 7, e40385, doi: 10.1371\/journal.pone.0040385 (2012).","journal-title":"PLoS One"},{"key":"BFsrep20617_CR18","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1038\/ncomms3836","volume":"4","author":"KJ Ewer","year":"2013","unstructured":"Ewer, K. J. et al. Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. Nat Commun 4, 2836, doi: 10.1038\/ncomms3836 (2013).","journal-title":"Nat Commun"},{"key":"BFsrep20617_CR19","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/mt.2013.248","volume":"22","author":"N Borthwick","year":"2014","unstructured":"Borthwick, N. et al. Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1. Mol Ther 22, 464\u2013475, doi: 10.1038\/mt.2013.248 (2014).","journal-title":"Mol Ther"},{"key":"BFsrep20617_CR20","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/mt.2013.284","volume":"22","author":"RD Antrobus","year":"2014","unstructured":"Antrobus, R. D. et al. Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens. Mol Ther 22, 668\u2013674, doi: 10.1038\/mt.2013.284 (2014).","journal-title":"Mol Ther"},{"key":"BFsrep20617_CR21","doi-asserted-by":"crossref","unstructured":"Swadling, L. et al. A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory. Sci Transl Med 6, 261ra153, doi: 10.1126\/scitranslmed.3009185 (2014).","DOI":"10.1126\/scitranslmed.3009185"},{"key":"BFsrep20617_CR22","doi-asserted-by":"crossref","unstructured":"Green, A. G. et al. Chimpanzee adenovirus\u2013 and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults. Sci Transl Med 7, 300ra126 (2015).","DOI":"10.1126\/scitranslmed.aac5745"},{"key":"BFsrep20617_CR23","doi-asserted-by":"crossref","unstructured":"Rampling, T. et al. A Monovalent Chimpanzee Adenovirus Ebola Vaccine - Preliminary Report. N Engl J Med, doi: 10.1056\/NEJMoa1411627 (2015).","DOI":"10.1056\/NEJMoa1411627"},{"key":"BFsrep20617_CR24","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1186\/1743-422X-10-349","volume":"10","author":"GM Warimwe","year":"2013","unstructured":"Warimwe, G. M. et al. Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley fever vaccine in mice. Virol J 10, 349, doi: 10.1186\/1743-422X-10-349 (2013).","journal-title":"Virol J"},{"key":"BFsrep20617_CR25","doi-asserted-by":"crossref","unstructured":"Lorenzo, G., Lopez-Gil, E., Warimwe, G. M. & Brun, A. Understanding Rift Valley fever: Contributions of animal models to disease characterization and control. Mol Immunol, doi: 10.1016\/j.molimm.2015.02.001 (2015).","DOI":"10.1016\/j.molimm.2015.02.001"},{"key":"BFsrep20617_CR26","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1089\/vbz.2009.0205","volume":"10","author":"N Busquets","year":"2010","unstructured":"Busquets, N. et al. Experimental infection of young adult European breed sheep with Rift Valley fever virus field isolates. Vector Borne Zoonotic Dis 10, 689\u2013696, doi: 10.1089\/vbz.2009.0205 (2010).","journal-title":"Vector Borne Zoonotic Dis"},{"key":"BFsrep20617_CR27","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1016\/j.vaccine.2014.02.066","volume":"32","author":"HM Weingartl","year":"2014","unstructured":"Weingartl, H. M., Miller, M., Nfon, C. & Wilson, W. C. Development of a Rift Valley fever virus viremia challenge model in sheep and goats. Vaccine 32, 2337\u20132344, doi: 10.1016\/j.vaccine.2014.02.066 (2014).","journal-title":"Vaccine"},{"key":"BFsrep20617_CR28","first-page":"155","volume":"50","author":"BJ Barnard","year":"1979","unstructured":"Barnard, B. J. Rift Valley fever vaccine--antibody and immune response in cattle to a live and an inactivated vaccine. J S Afr Vet Assoc 50, 155\u2013157 (1979).","journal-title":"J S Afr Vet Assoc"},{"key":"BFsrep20617_CR29","doi-asserted-by":"publisher","first-page":"4581","DOI":"10.1016\/j.vaccine.2010.04.085","volume":"28","author":"B Dungu","year":"2010","unstructured":"Dungu, B. et al. Evaluation of the efficacy and safety of the Rift Valley Fever Clone 13 vaccine in sheep. Vaccine 28, 4581\u20134587, doi: 10.1016\/j.vaccine.2010.04.085 (2010).","journal-title":"Vaccine"},{"key":"BFsrep20617_CR30","doi-asserted-by":"publisher","first-page":"5771","DOI":"10.1016\/j.vaccine.2011.05.055","volume":"29","author":"B von Teichman","year":"2011","unstructured":"von Teichman, B. et al. Safety and efficacy of Rift Valley fever Smithburn and Clone 13 vaccines in calves. Vaccine 29, 5771\u20135777, doi: 10.1016\/j.vaccine.2011.05.055 (2011).","journal-title":"Vaccine"},{"key":"BFsrep20617_CR31","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.antiviral.2014.03.008","volume":"106","author":"J Kortekaas","year":"2014","unstructured":"Kortekaas, J. One Health approach to Rift Valley fever vaccine development. Antiviral Research 106, 24\u201332, doi: 10.1016\/j.antiviral.2014.03.008 (2014).","journal-title":"Antiviral Research"},{"key":"BFsrep20617_CR32","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1089\/vbz.2014.1650","volume":"14","author":"B Faburay","year":"2014","unstructured":"Faburay, B. et al. A glycoprotein subunit vaccine elicits a strong Rift Valley fever virus neutralizing antibody response in sheep. Vector Borne Zoonotic Dis 14, 746\u2013756, doi: 10.1089\/vbz.2014.1650 (2014).","journal-title":"Vector Borne Zoonotic Dis"},{"key":"BFsrep20617_CR33","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/521405a","volume":"521","author":"EC Hayden","year":"2015","unstructured":"Hayden, E. C. Ebola R & D woes spur action. Nature 521, 405\u2013406, doi: 10.1038\/521405a (2015).","journal-title":"Nature"},{"key":"BFsrep20617_CR34","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1038\/nature06536","volume":"451","author":"KE Jones","year":"2008","unstructured":"Jones, K. E. et al. Global trends in emerging infectious diseases. Nature 451, 990\u2013U994, doi: 10.1038\/nature06536 (2008).","journal-title":"Nature"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep20617.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep20617","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep20617.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T03:06:12Z","timestamp":1672887972000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep20617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,5]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,2,22]]}},"alternative-id":["BFsrep20617"],"URL":"https:\/\/doi.org\/10.1038\/srep20617","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,5]]},"assertion":[{"value":"23 September 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20617"}}